SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus-Reference-Cited by-同舟云学术

SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus

Published:2018-02 Issue: Volume:136 Page:23-31
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

d'Emden Michael^ORCID,Amerena John^ORCID,Deed Gary,Pollock Carol,Cooper Mark E.

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference61 articles.

1. Predicting cardiovascular risk in type 2 diabetes: the heterogeneity challenges;Gore;Curr Cardiol Rep,2015

2. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies;Sarwar;Lancet,2010

3. Royal Australian College of General Practitioners and Diabetes Australia. General practice management of type 2 diabetes 2016–2018. 2016. Available at: [accessed 6 Dec 2016].

4. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

5. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients;Scientific Reports;2023-10-27

2. Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea;Pharmacology Research & Perspectives;2022-01-10

3. Infectious complications of newer agents in the fight against diabetes;The Nurse Practitioner;2020-11

4. Management of sodium–glucose cotransporter 2 inhibitors during the perioperative period: A retrospective comparative study;Journal of Perioperative Practice;2020-09-08

5. Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey;Diabetes and Vascular Disease Research;2020-07